SCHOTT Pharma Exceeds Q2 2025 Market Expectations

SCHOTT Pharma AG & Co. KGaA reports that its preliminary figures for the second quarter of 2025 surpass market forecasts. The company anticipates Q2 revenues of EUR 252 million, marking a 10% increase year-over-year at constant currencies. The expected EBITDA stands at EUR 72 million, with a corresponding margin of 28.6%.

These results outstrip the current market consensus of EUR 242 million in revenue and EUR 62 million EBITDA with a 25.5% margin, according to research from Vara. Despite these higher figures, SCHOTT Pharma maintains its existing full-year guidance for fiscal 2025, as previously outlined in December 2024.

Complete details of SCHOTT Pharma's second quarter and first half of 2025 results will be released on May 15, 2025.